Analytical Data
-
Gene name
IL-17RA
- Application
-
Alternative Names
CDw217; CD217; IL17R-A; IL17-RA; IL17R-A; IL17R; HIL-17R
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by reducing SDS-PAGE.
-
Uniprot
D4A740
-
Expression Region
Gly617~Gly847
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-17 receptor A (IL-17RA) is a crucial component of the IL-17 signaling pathway, which plays a significant role in mediating inflammatory responses and is implicated in various autoimmune diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis. The IL-17 family of cytokines, which includes IL-17A, IL-17F, and others, binds to IL-17RA to activate downstream signaling cascades that result in the production of pro-inflammatory cytokines and chemokines. Due to its pivotal role in the immune response, IL-17RA has emerged as a promising therapeutic target. Research into recombinant protein forms of IL-17RA aims to better understand its structure, function, and interaction with other molecules within the immune system. Recombinant IL-17RA proteins can be utilized to develop biologics that inhibit these pathways, potentially providing new treatment options for patients suffering from IL-17-mediated diseases. Additionally, studying IL-17RA may reveal insights into its involvement in normal immune function and help delineate its contributions to disease pathogenesis. Thus, the exploration of IL-17RA recombinant proteins not only enhances our understanding of immune regulation but also holds significant promise for innovative therapeutic strategies in managing a range of inflammatory disorders.
